Drug intelligence / Profile preview

QLH12016

Development stage: Phase 2
Lead developer: Qilu Pharmaceutical
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Oral

Overview

QLH12016 is an investigational small molecule drug developed by Qilu Pharmaceutical for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is currently in phase 1 clinical trials, where its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity are being evaluated. The precise mechanism of action has not been publicly disclosed; however, some sources suggest it may target SMARCA2 and could be a PROTAC (proteolysis-targeting chimera) degrader. The drug is administered orally and is being studied primarily in China[1][2][4][6].

Other names: QLH12016QLH-12016QLH 12016

Targets

SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily A member 2)CRBN (Cereblon)

Beyond the preview

Go deeper on QLH12016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QLH12016.

Explore the full profile